Do some prescriptive sleeping pills posses a danger?

Novel class of sleeping pills might prevent ability to wake in response to threat

15-Jan-2019 - In a trial of one of the main class of prescription sleeping pills, half the participants slept through a fire alarm as loud as someone vacuuming next to their bed. But a newer alternative preserves the ability to wake in response to danger signals, according to a new research. The study showed ...

BioInvent reports clinical hold on BI-505 phase II study

09-Nov-2016 - BioInvent International has received verbal notice from the U.S. Food and Drug Administration that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInvent has not ...

Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema

30-Nov-2010 - Pharming Group NV announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor ("rhC1INH") in patients with Hereditary Angioedema (HAE). The study is an open-label exploratory phase II study of the safety and prophylactic effect ...

Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

17-Nov-2010 - Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and the ...

Action Pharma initiates phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

10-Nov-2010 - Action Pharma A/S has administered the first dose to the first patient in a phase IIb clinical trial being undertaken in the USA and Denmark with its leading drug candidate AP214. This follows the positive results obtained on safety, tolerability and efficacy in the phase IIa clinical trial ...

AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316

09-Nov-2010 - AiCuris announced the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing. AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the ...

Hybrigenics develops new oral formulations of inecalcitol

Hybrigenics seeks patent protection until 2030 for innovative oral formulations optimized for the delivery of high doses of inecalcitol

04-Nov-2010 - Hybrigenics announced the filing of a patent application covering new soft gelatin capsules, tablets or drinking solutions optimized for the delivery of high doses of inecalcitol. This pharmaceutical optimization followed the demonstration of safety and the presumption of efficacy of oral doses ...

Shield Signs Agreement for ST10-021 with AOP Orphan Pharmaceuticals

AOP Orphan to make strategic €3m investment in Shield Holdings

02-Nov-2010 - Shield Holdings AG announced that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG (“AOP”). Under the terms of the agreement, Shield, whose products ...

Trophos initiates pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

19-Oct-2010 - Trophos SA announced the initiation of the pivotal efficacy study of olesoxime in the rare, neurodegenerative condition, Spinal Muscular Atrophy (SMA). The study is substantially funded by Trophos’ partnership with the Association Française contre les Myopathies (AFM). The trial protocol has ...

Phosphagenics moves towards scale-up patch manufacturing after positive clinical results

TPM patch profile ideal for the treatment of chronic pain

18-Oct-2010 - Melbourne drug delivery company Phosphagenics Limited is set to move from lab-scale development into commercial patch manufacturing after successfully completing its product profiling phase 1 study. This milestone study, led by Professor Guy Ludbrook at the Royal Adelaide Hospital, involved ...